Ironwood Pharmaceuticals Inc. (IRWD) is priced at $ 12.61 after the last trading session. At the very opening of the session, the stock price was $ 12.90 and reached a high price of $ 13.21, before closing the session, it reached the value of $ 13.20. The stock reached a low price of $ 12.88. Recently in News on November 4, 2021, Ironwood Pharmaceuticals reported third quarter 2021 results and provided an update on the development of the company. – The growth in demand for prescriptions for LINZESSÂ® (Iinaclotide) increased by 12% year-on-year; LINZESS US net sales of $ 253 million, an increase of 5% year-on-year. You can read more details here
Ironwood Pharmaceuticals Inc. has had a fairly favorable track record in terms of market performance. The highest one-year price for the company’s stock is recorded at $ 14.27 on 12/08/21, with the lowest value being $ 8.78 for the same period, recorded on 02/26 / 21.
The annual performance of Ironwood Pharmaceuticals Inc. (IRWD) was 23.71%
Price records that include historical low and high prices over a 52 week period can say a lot about the current state of the stock and future performance. Currently shares of Ironwood Pharmaceuticals Inc. are -11.63% over the 52 week period from the high price, and 43.59% higher than the low price for the same period. The share price range for the 52 week period managed to keep performance between $ 8.78 and $ 14.27.
Shares of the company, operating in the healthcare sector, managed to break above a trading volume of around 1,461,714 for the day, which was obviously lower than the average daily volumes of the shares.
Looking at the year-to-date metrics, Ironwood Pharmaceuticals Inc.’s (IRWD) performance in the market was 15.89%, with revenues of -2.15% on a quarterly basis compared to at the same period the previous year. At the time of this writing, the total market value of the company is set at 2.10 billion, as it employs a total of 232 workers.
Specialist analysis on Ironwood Pharmaceuticals Inc. (IRWD)
In the past month, 0 analysts rated Ironwood Pharmaceuticals Inc. a BUY rating, 0 of analysts surveyed rated the stock as OVERWEIGHT, 0 analysts recommended KEEP this stock, 0 of them rated the stock as OVERWEIGHT, 0 analysts rated this stock as UNDERWEIGHT rating and 0 of the analysts surveyed provided a SELL rating.
According to data provided on Barchart.com, the company’s moving average over the 100-day period was set at 12.98, with a price change noted +0.82. Likewise, Ironwood Pharmaceuticals Inc. posted a movement of + 7.04% for the last 100 days, registering 1,872,319 in transaction volumes.
The ratio of total debt to equity (D / E) can also provide valuable information about the financial health of the company and the state of the market. The debt ratio can be calculated by dividing a company’s current total liabilities by equity. Debt to equity is therefore a valuable metric that describes the debt that the company uses to support assets, correlated with the value of equity. The total debt to equity ratio for IRWD is 0.86 at the time of writing. In addition, the long-term debt to equity ratio is set at 0.64.
>> 7 top choices for the post-pandemic economy
Trends and Technical Analysis: Ironwood Pharmaceuticals Inc. (IRWD)
Ironwood Pharmaceuticals Inc.’s gross stochastic average over the past 50 days is set at 29.45%. The result represents an improvement over the raw stochastic mean for the last 20 days of 22.71%. In the past 20 days, the company’s stochastic% K was 38.59% and its stochastic% D was recorded at 34.97%.
Now, considering the previous presentation of the stocks, several moving trends are noted. Year-to-date, the company’s stock price performance appears to be pessimistic, as the metric registers 15.89%. Additionally, the stock’s trading over the past six months has improved significantly by 20.11%, alongside an increase of 23.71% for the past 12-month period. Shares are up around 2.09% in the 7-day charts and are up -5.38% in the past 30 days. Common shares rose -2.15% in the last recorded quarter.